Liquid Biopsy to Identify Actionable Genomic Alterations
نویسندگان
چکیده
منابع مشابه
Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas
BACKGROUND There are currently no United States Food and Drug Administration approved molecularly matched therapies for sarcomas except gastrointestinal stromal tumors. Complicating this is the extreme diversity, heterogeneity, and rarity of these neoplasms. Few therapeutic options exist for relapsed and refractory sarcomas. In clinical practice many oncologists refer patients for genomic profi...
متن کاملLearning to Identify Locally Actionable Health Anomalies
Local information access (LIA) programs tap into existing public health data flows, and present data in simple and useful ways to ground staff. LIAs hold great potential for improving rural health systems in developing regions; benefits include more evidence-based decision making and optimizations at a local scale, as well as improved service delivery and data quality. Our fledgling LIA program...
متن کاملLiquid Biopsy as a Minimally Invasive Source of Thyroid Cancer Genetic and Epigenetic Alterations
In the blood of cancer patients, some nucleic acid fragments and tumor cells can be found that make it possible to trace tumor changes through a simple blood test called “liquid biopsy”. The main components of liquid biopsy are fragments of DNA and RNA shed by tumors into the bloodstream and circulate freely( ctDNAs and ctRNAs). tumor cells which are shed into the blood (circulating tumor cells...
متن کاملHigh-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing.
UNLABELLED Knowledge of "actionable" somatic genomic alterations present in each tumor (e.g., point mutations, small insertions/deletions, and copy-number alterations that direct therapeutic options) should facilitate individualized approaches to cancer treatment. However, clinical implementation of systematic genomic profiling has rarely been achieved beyond limited numbers of oncogene point m...
متن کاملPrevalence of actionable mutations and copy number alterations and the price of a genomic testing panel
Interest in genomic testing for the selection of cancer therapy is growing. However, the cost of genomic testing has not been well studied. We sought to determine the price of identifying mutations and copy number alterations (CNAs) in theoretically actionable genes across multiple tumor types. We reviewed data from The Cancer Genome Atlas to determine the frequency of alterations in nine tumor...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: American Society of Clinical Oncology Educational Book
سال: 2018
ISSN: 1548-8748,1548-8756
DOI: 10.1200/edbk_199765